Clinical Trial Update: Polyvalent Immunoglobulin in COVID-19 Related ARds [Phase 3]

View source ↗

Summary

Phase 3 trial update on polyvalent immunoglobulin for COVID-19 related acute respiratory distress syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• polyvalent immunoglobulin

Snippet

Sponsor: Centre Hospitalier St Anne | Conditions: Acute Respiratory Distress Syndrome, COVID-19 | Phase 3 | Status: COMPLETED